Breast cancer enzyme Nr. 4
Breast cancer
With around 67,300 new cases annually, breast cancer is by far the most common cancer in women. In addition, more than 6,000 women are diagnosed with in situ tumors every year.
About 1 percent of all new cases affect men. Based on the current incidence rates, around one in eight women will develop breast cancer at some point in their lives. Almost three in ten women affected are younger than 55 years of age when the diagnosis is made.
New illness and death rates are still lower in the new federal states than in the old federal states; only for women up to 55 years have the rates largely equalized.
Our Frala-biotech breast cancer enzyme No. 4 specifically helps to slow down the growth and spread of cancer cells in the organism. Cancer cells employ various strategies to avoid being destroyed by the body's immune defenses. For example, they camouflage themselves with a cover made of an endogenous material and can thus migrate to other parts of the body undetected. Our Frala-biotech Breast Cancer Enzyme No. 4 recognizes these camouflaged cells and destroys them. This way, metastases can be effectively prevented. Another deception maneuver of the cancer cells is also undermined by our Frala-biotech cancer enzyme: The cancer cells produce structures that are classified as harmful and attacked by the immune system. Cancer cells that are still alive remain unmolested and have a free path to multiply. Our Frala-biotech Breast Cancer Enzyme No. 4 is able to split the deceptive structures.
Recommended daily dose: 2 x 1 capsule
